Novavax To Participate In Upcoming September Conferences
(MENAFN- PR Newswire)
GAITHERSBURG, Md., Sept. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX ), a global company advancing protein-based vaccines with its novel Matrix-MTM adjuvant, today announced that it will participate in two upcoming investor conferences.
| H.C. Wainwright 26th Annual Global investment Conference: |
| Fireside Chat |
|
| Date: |
Monday, September 9, 2024 |
| Time: |
3:30 – 4:00 p.m. Eastern Time (ET) |
| Location: |
New York City, New York |
| Moderator: |
Vernon Bernardino, Managing Director, Senior Healthcare Analyst |
| Novavax participants: |
Jim Kelly, Executive Vice President, Chief Financial Officer and Treasurer and Robert Walker, MD, Senior Vice President, Chief Medical Officer and Interim Head, Research and Development |
|
|
| Conference |
|
| Event: |
Investor Meetings |
| Date: |
Monday, September 9, 2024 |
|
|
|
| Baird 2024 Global Healthcare Conference: |
| Presentation |
|
| Date: |
Tuesday, September 10, 2024 |
| Time: |
3:10 – 3:40 p.m. ET |
| Location: |
New York City, New York |
| Novavax participants: |
Jim Kelly, Executive Vice President, Chief Financial Officer and Treasurer and Robert Walker, MD, Senior Vice President, Chief Medical Officer and Interim Head, Research and Development |
|
|
| Conference |
|
| Event: |
Investor Meetings |
| Date: |
Tuesday, September 10, 2024 |
|
|
A replay of the recorded fireside session and presentation will be available through the Events and Presentations page of the Company's website at href="" rel="nofollow" novava
for 30 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX ) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination
and stand-alone influence vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax
and LinkedIn
for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
[email protected]
Media
Giovanna Chandler
202-709-5563
[email protected]
SOURCE Novavax, Inc.
MENAFN04092024003732001241ID1108635861
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.